3D-QSAR and docking studies of benzoyl urea derivatives as tubulin-binding agents for antiproliferative activity

[1]  D. Shinde,et al.  Synthesis, biological activity and docking study of imidazol-5-one as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2012, Bioorganic & medicinal chemistry.

[2]  Devanand Shinde,et al.  Development of energetic pharmacophore for the designing of 1,2,3,4-tetrahydropyrimidine derivatives as selective cyclooxygenase-2 inhibitors , 2012, Journal of Computer-Aided Molecular Design.

[3]  Woody Sherman,et al.  ConfGen: A Conformational Search Method for Efficient Generation of Bioactive Conformers , 2010, J. Chem. Inf. Model..

[4]  Maria Kavallaris,et al.  Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.

[5]  Jian-Dong Jiang,et al.  Synthesis and activity evaluation of phenylurea derivatives as potent antitumor agents. , 2009, Bioorganic & medicinal chemistry.

[6]  Qiang Zhang,et al.  Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. , 2009, Cancer research.

[7]  Jian-Dong Jiang,et al.  Synthesis and activity evaluation of benzoylurea derivatives as potential antiproliferative agents. , 2009, Bioorganic & medicinal chemistry letters.

[8]  Jian-Dong Jiang,et al.  Benzoylurea derivatives as a novel class of antimitotic agents: synthesis, anticancer activity, and structure-activity relationships. , 2008, Journal of medicinal chemistry.

[9]  David G. I. Kingston,et al.  Tubulin-interactive natural products as anticancer agents. , 2008, Journal of natural products.

[10]  D. Boykin,et al.  3-(2'-Bromopropionylamino)-benzamides as novel S-phase arrest agents. , 2007, Bioorganic & medicinal chemistry letters.

[11]  Jacek Gaertig,et al.  The Tubulin Code , 2007, Cell cycle.

[12]  K. Balakin,et al.  Recent progress in discovery and development of antimitotic agents. , 2007, Anti-cancer agents in medicinal chemistry.

[13]  Jeffrey R. Jackson,et al.  Targeted anti-mitotic therapies: can we improve on tubulin agents? , 2007, Nature Reviews Cancer.

[14]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[15]  D. Budman,et al.  Review: Tubulin Function, Action of Antitubulin Drugs, and New Drug Development , 2005, Cancer investigation.

[16]  T. Fojo,et al.  The clinical development of new mitotic inhibitors that stabilize the microtubule. , 2004, Anti-cancer drugs.

[17]  E. Rubin,et al.  Epothilones: mechanism of action and biologic activity. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[19]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[20]  Jian-Dong Jiang,et al.  Inhibition of microtubule polymerization by 3-bromopropionylamino benzoylurea (JIMB01), a new cancericidal tubulin ligand. , 2003, Biochemical pharmacology.

[21]  P. Elliott,et al.  Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Beom-Tae Kim,et al.  Novel benzoylurea derivatives as potential antitumor agents; synthesis, activities and structure-activity relationships , 2002, Archives of pharmacal research.

[23]  R. Perez-soler,et al.  Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand. , 2002, Cancer research.

[24]  H. Sham,et al.  Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer , 2002 .

[25]  P. Elliott,et al.  PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. , 2002, Molecular cancer therapeutics.

[26]  T. Fojo,et al.  Tubulin/microtubules: still a promising target for new chemotherapeutic agents. , 2000, Journal of the National Cancer Institute.

[27]  A. Yamaguchi,et al.  Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. , 1997, Cancer research.

[28]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[29]  D. Alberts,et al.  Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 , 1989, Experientia.

[30]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[32]  T. Beckers,et al.  Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy , 2003 .